CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 60 enrolled
Drug / intervention
paclitaxel +3 moredrug
Likely dose
paclitaxel 175mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00360360
NCT00360360Phase 2Completed
CompareCT.gov

A Phase II Study of Paclitaxel/Carboplatin Plus Bevacizumab/Erlotinib in the First Line Treatment of Patients With Carcinoma of Unknown Primary Site

SCRI Development Innovations, LLC·interventional·Posted Aug 4, 2006·Updated Dec 4, 2013

In Brief

A Phase 2 clinical trial evaluating paclitaxel, carboplatin, and 2 other interventions for Neoplasm, Unknown Primary. Completed, enrolled 60 participants across 9 sites.

Detailed Summary

We will evaluate the feasibility, toxicity, and effectiveness of combination chemotherapy (paclitaxel/carboplatin)plus combination targeted therapy (bevacizumab/erlotinib)in the first line treatment of patients with carcinoma of unknown primary site. There is limited experience with either bevacizumab or erlotinib in the treatment of cancers of unknown site but given the heterogeneous nature of the tumor, it is likely that inhibition of angiogenesis pathways and/or the EGFR pathway are effective strategies in at least a proportion.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasm, Unknown Primary
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 4, 2006
Enrollment StartJul 1, 2006
Primary CompletionFeb 1, 2008
Study CompletionMar 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 19.9 years ago

Interventions

paclitaxeldrug

Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1

carboplatindrug

Carboplatin AUC 6.0 IV Day 1

bevacizumabdrug

Bevacizumab 15mg/kg IV infusion,Day 1

erlotinibdrug

Erlotinib 150 mg by mouth daily